Sagimet Biosciences Inc Series A Common Stock (SGMT) had the highest return between December 27, 2023 and January 22, 2024 by a small-cap US stock, returning 209.6%.
| ASSET | DATE | % RETURN |
|---|---|---|
Sagimet Biosciences Inc Series A Common Stock (SGMT) | 12/27/2023 - 1/22/2024 | 209.58% |
Neurogene (NGNE) | 12/27/2023 - 1/22/2024 | 98.15% |
Clene (CLNNW) | 12/27/2023 - 1/22/2024 | 89.97% |
Praxis Precision Medicines (PRAX) | 12/27/2023 - 1/22/2024 | 69.96% |
Real Brokerage (REAX) | 12/27/2023 - 1/22/2024 | 64.97% |
Immunome (IMNM) | 12/27/2023 - 1/22/2024 | 53.73% |
QuantaSing Group Limited American Depositary Shares (QSG) | 12/27/2023 - 1/22/2024 | 50.6% |
Establishment Labs (ESTA) | 12/27/2023 - 1/22/2024 | 48.38% |
SEALSQ (LAES) | 12/27/2023 - 1/22/2024 | 48.21% |
Edgewise Therapeutics (EWTX) | 12/27/2023 - 1/22/2024 | 48.1% |
Neuropace (NPCE) | 12/27/2023 - 1/22/2024 | 47.22% |
Dianthus Therapeutics (DNTH) | 12/27/2023 - 1/22/2024 | 42.61% |
Spyre Therapeutics (SYRE) | 12/27/2023 - 1/22/2024 | 40.06% |
Yirendai (YRD) | 12/27/2023 - 1/22/2024 | 39.8% |
Keros Therapeutics (KROS) | 12/27/2023 - 1/22/2024 | 36.03% |
Ardelyx (ARDX) | 12/27/2023 - 1/22/2024 | 35.07% |
Abacus Life (ABL) | 12/27/2023 - 1/22/2024 | 35.01% |
ATAI Life Sciences (ATAI) | 12/27/2023 - 1/22/2024 | 33.82% |
American Public Education (APEI) | 12/27/2023 - 1/22/2024 | 33.82% |
Capital Clean Energy Carriers (CCEC) | 12/27/2023 - 1/22/2024 | 33.78% |
Akso Health Group ADR (AHG) | 12/27/2023 - 1/22/2024 | 33.68% |
Qilian International (BGM) | 12/27/2023 - 1/22/2024 | 32.08% |
Y mAbs Therapeutics (YMAB) | 12/27/2023 - 1/22/2024 | 30.79% |
Net Lease Office Properties (NLOP) | 12/27/2023 - 1/22/2024 | 29.38% |
Verastem (VSTM) | 12/27/2023 - 1/22/2024 | 28.85% |
Small-cap stocks are treated as having a market cap between $300M and $2B.
